Interferon
Trovati 46 articoli
- Telbivudine: risk of peripheral neuropathy with Pegylated Interferon
- Telbivudine ( Sebivo ) is a new nucleoside analogue that is indicated for treatment of chronic hepatitis B in adults with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase ( ALT ), and histological evidence of active inflammation or... (Leggi Articolo)
- Association of Tysabri with progressive multifocal leukoencephalopathy
- At the end of July 2008, two cases of progressive multifocal leukoencephalopathy ( PML ) were reported in patients with multiple sclerosis receiving Natalizumab ( Tysabri ) in the European post-marketing setting. PML is a subacute evolving CNS disease caused by reactivation of JC virus predomi... (Leggi Articolo)
- Microangiopathic hemolytic anemia in patients treated with Bevacizumab plus Sunitinib
- The safety and maximum tolerated dose ( MTD ) of sunitinib malate( Sutent ) in combination with Bevacizumab ( Avastin ) has been assessed in patients with metastatic renal cell carcinoma ( mRCC ) in a phase I study, exploring 3 cohorts using a fixed dose of Avastin at 10 mg/kg/IV every 2 weeks an... (Leggi Articolo)
- Advanced renal cell carcinoma: Temsirolimus improves overall survival
- The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show Temsirolimus ( Torisel ) improved overall survival when compared to the current treatment for this stage of disease. The study was led by Gary R. Hudes, a... (Leggi Articolo)
- Chronic hepatitis C: treatment with Interferon linked to retinopathy
- Individuals with chronic hepatitis C being treated with Interferon ( IFN ) are at risk of developing retinopathy as early as two weeks into treatment according to the results of a study published in the Investigative Ophthalmology & Visual Science ( IOVS ). Researchers at Asahikawa Medical Co... (Leggi Articolo)
- Hepatocellular carcinoma: Nexavar significantly prolongs overall survival
- Sorafenib ( Nexavar ) tablets has significantly extended overall survival in patients with hepatocellular carcinoma ( HCC ), or primary liver cancer versus those taking placebo by 44% ( HR=0.69; p-value=0.0006 ). The Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol ( SH... (Leggi Articolo)
- Once-weekly Pegasys allows to achieve viral clearance in patients not responding to Peg-Intron in HCV patients
- Final results from the REPEAT study have demonstrated that treatment with once-weekly Pegasys ( Peginterferon alfa-2a ) and daily Copegus ( Ribavirin ) can achieve viral clearance in a number of patients who did not respond to initial treatment with Peg-Intron ( Peginterferon alfa-2b ). This... (Leggi Articolo)
- Broccoli and related vegetables: DIM can boost immune system
- A compound found in broccoli and related vegetables may have more health-boosting tricks up its sleeves. The 3,3'-diindolylmethane ( DIM ), a chemical produced from the compound indole-3-carbinol when Brassica vegetables such as broccoli, cabbage and kale are chewed and digested, has some canc... (Leggi Articolo)
- Gleevec proves safe and effective over the long term in chronic myeloid leukemia
- The drug Imatinib mesylate, more commonly known as Gleevec ( Europe: Glivec ), proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia ( CML ). A team of researchers followed 454 patients with chronic-phase chronic myeloid leukemia taking Imat... (Leggi Articolo)
- Signaling proteins may represent biomarkers for melanoma
- Researchers studying patients with abnormal moles have identified proteins that could help predict whether such moles will progress into melanoma, the deadliest form of skin cancer. The study provides promising evidence that the proteins may represent potential biomarkers for prevention therapy. ... (Leggi Articolo)
- MabCampath more effective than Rebif in relapsing-remitting multiple sclerosis
- Two-year interim results from a Phase 2 trial comparing MabCampath ( Alemtuzumab; Campath ) with Rebif ( Interferon beta-1a ) for the treatment of multiple sclerosis have demonstrated statistically significant efficacy of Campath compared to Rebif. The phase 2 trial randomized 334 patients wit... (Leggi Articolo)
- Cyclosporine inhibits HCV virus in vitro
- Liver transplant patients with hepatitis C virus ( HCV ) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine ( Sandimmun Neoral ) along with Interferon-Ribavirin combination therapy. Cyclosporine also showed efficacy against hepatitis C vi... (Leggi Articolo)
- Hepatitis C: difficulty in treating older patients with Interferon and Ribavirin
- A study in Japan examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits in this age group. Chronic hepatitis C virus ( HCV ), the most common cause... (Leggi Articolo)
- Hepatitis C: weight loss improves the efficacy of therapy
- Obese patients chronically infected with the hepatitis C virus ( HCV ) and treated with combination drug therapy may have better outcomes if the underlying abnormalities caused by excessive fat tissue are corrected. Weight loss, medications to decrease insulin resistance and extending duration ... (Leggi Articolo)
- Advanced kidney cancer: Sutent shows significant benefits over Interferon-alpha
- Sunitinib ( Sutent ) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma ( mRCC ). " Sunitinib has shown more activity as a single agent against advanced kidney cancer... (Leggi Articolo)
- High overall survival after five years on Imatinib in chronic myelogenous leukemia
- A study of the Oregon Health & Science University ( OHSU ) Cancer Institute has shown that the overall survival of most people with chronic myelogenous leukemia ( CML ) treated with Imatinib ( Gleevec / Glivec, STI-571 ) is extremely high and the relapse rate is quite low. The overall surviva... (Leggi Articolo)
- FDA has approved the reintroduction of Tysabri in relapsing multiple sclerosis
- The FDA ( U.S. Food and Drug Administration ) has approved the reintroduction of Tysabri ( Natalizumab ) as a monotherapy treatment for relapsing forms of multiple sclerosis to slow the progression of disability and reduce the frequency of clinical relapses. TYSABRI will be available upon th... (Leggi Articolo)
- Sunitinib is a promising drug for treatment of metastatic renal cell cancer
- A study suggests that Sunitinib ( Sutent ) is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options. The study is published in the JAMA. There is an urgent need for more active agents for the treatment of metastatic ... (Leggi Articolo)
- Multiple sclerosis: Epstein-Barr virus may increase risk
- Researchers have found that patients with multiple sclerosis carry a population of immune cells that overreact to Epstein-Barr virus. The virus, which causes mononucleosis and may contribute to some cancers, has long been suspected to play a role in multiple sclerosis. However, the mechanism lin... (Leggi Articolo)
- Advanced renal cell carcinoma: efficacy of Lapatinib in patients with high EGFR expression
- A phase III clinical trial has shown that Lapatinib ( Tykerb ) slows cancer growth and improves survival in a subset of patients with an advanced renal cell carcinoma ( RCC ) that continued to grow despite standard therapy. The patients in the study who responded favorably to this drug had tumor... (Leggi Articolo)
- Combination of Interleukin-12 and Interferon appears to be safe
- A research has shown that the immune-stimulating hormone known as Interleukin-12 ( IL-12 ) can safely be administered with Interferon, another immune-system protein, as an experimental therapy for some cancers. Normally, Interferon is used alone to stimulate the immune system to attack certai... (Leggi Articolo)
- Interleukin-12 can safely be administered with Interferon as an experimental therapy for some cancers
- A study has shown that the immune-stimulating hormone known as Interleukin-12 ( IL-12 ) can safely be administered with Interferon, another immune-system protein, as an experimental therapy for some cancers. Normally, Interferon is used alone to stimulate the immune system to attack certain c... (Leggi Articolo)
- Children with chronic hepatitis C: Interferon with Ribavirin is safe and effective
- Nearly half of 118 children with chronic Hepatitis C virus ( HCV ) treated with a combination of Interferon-alpha-2b ( Intron A ) and an optimized dose of Ribavirin ( Rebetol ) achieved sustained viral response, and side effects were generally mild. These results are reported in the journal He... (Leggi Articolo)
- Langat flavivirus, NS5 allows to evade the host immune system
- Researchers from the National Institute of Allergy and Infectious Diseases ( NIAID ), part of the National Institutes of Health ( NIH ), have made the surprising discovery that flaviviruses, which cause such serious diseases as West Nile fever, yellow fever and forms of encephalitis, evade immune... (Leggi Articolo)
- Chronic myeloid leukemia: advances in therapy
- The results from five studies highlighting new advances in the treatment of chronic myeloid leukemia ( CML ) – a slow-progressing, malignant bone marrow cancer – have been presented at the 47th Annual Meeting of the American Society of Hematology. " The survival rate for leukemia has improved... (Leggi Articolo)
- Intralesional immunotherapy of warts may be particularly useful in patients with numerous lesions
- Injection of skin test antigens into warts appears to stimulate the immune system and successfully treat the injected wart and also helps to treat distant non-injected warts Warts are unsightly and often tender or painful, causing most patients with warts to seek treatment. Primary treatment u... (Leggi Articolo)
- Peg-Intron plus Rebetol in children and adolescents with chronic hepatitis C
- More than half of 61 children and adolescents infected with chronic hepatitis C achieved a sustained viral response after treatment with Peginterferon-alfa-2b ( Peg-Intron ) and Ribavirin ( Rebetol ). Peginterferon plus Ribavirin is standard therapy for adults with chronic hepatitis C. As no d... (Leggi Articolo)
- Multiple sclerosis: Interferon does not affect duration of black hole lesions
- Although treatment with Interferon appears to reduce the formation of new areas of damage in the brains of patients with multiple sclerosis ( MS ), including lesions that appear as highly contrasted images, called black holes, on magnetic resonance imaging ( MRI ), treatment does not appear to a... (Leggi Articolo)
- Pegasys for the treatment of chronic hepatitis B, FDA approved
- The FDA ( Food and Drug Administration ) approved Pegasys ( Peginterferon alfa-2a ) for the treatment of chronic hepatitis B ( CHB ). Pegasys is the first and only pegylated Interferon approved for the treatment of chronic hepatitis B, including both variations of the virus - HBeAg-positive a... (Leggi Articolo)
- HCV infection: how virus evades the body’s immune system
- Researchers at Johns Hopkins have uncovered how a majority of the genetic changes in the hepatic-C virus, the most common cause of liver disease, allow it to evade the body’s immune system during infection. Hepatitis C infection can lead to cirrhosis, cancer and even death. In a series of e... (Leggi Articolo)
- New gene regulation mechanism discovered
- Researchers at Cold Spring Harbor Laboratory have discovered a new kind of messenger RNA molecule that is converted from non-protein coding status to protein coding status in response to cellular stress such as viral infection. The discovery reveals a "cut and run" mechanism that is likely to ... (Leggi Articolo)
- Peginterferon alfa-2a plus Ribavirin for chronic hepatitis C virus infection in HIV-infected patients
- The final statement from the 1st European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-infected Patients, includes a definitive recommendation that HIV patients co-infected with the hepatitis C virus (HCV) should be treated with Pegylated Interferon combination the... (Leggi Articolo)
- Pegasys as a first-line therapy in chronic hepatitis B
- Patients with the most common form of hepatitis B in the United States who are treated with Pegasys ( Peginterferon alfa-2a ) are more likely to achieve a sustained response than those treated with Lamivudine ( Epivir ), the current standard of care. In a Phase III study patients treated with ... (Leggi Articolo)
- FDA has approved Pegasys and Copegus for the treatment of chronic hepatitis C in HIV patients
- FDA ( Food and Drug Administration ) has approved Pegasys ( Peginterferon alfa-2a ) and Copegus ( Ribavirin ) for the treatment of chronic hepatitis C in patients co-infected with hepatitis C and HIV. Hepatitis C has become the most frequent cause of liver disease in HIV patients, and may be ... (Leggi Articolo)
- TRAF3 protein is a key part of the early immune response to viruses
- A protein called TRAF3, with a previously unknown job in immune cells, is actually a key part of a mechanism that triggers release of anti-virus molecules called type I Interferons ( IFNs ) as part of the body's rapid response against these invaders. The discovery of TRAF3's role helps to expl... (Leggi Articolo)
- Europe: Pegasys approved for the treatment of chronic hepatitis B
- European Commission has approved Pegasys ( Peginterferon alfa-2a ) for the treatment of chronic hepatitis B. The approval is granted for both types of the disease, HBeAg-positive and HBeAg-negative chronic hepatitis B. Pegasys achieves sustained remission in a significant number of patient... (Leggi Articolo)
- Hepatotoxicity of Interferon beta-1b, a drug for multiple sclerosis
- Berlex, according to FDA ( Food and Drug Administration ), informed HealthCare Professional about the safety profile of Interferon beta-1b ( Betaseron ). Since market introduction in 1993, the Betaseron prescribing information has recommended liver function testing at regular intervals ( one,... (Leggi Articolo)
- Mechanisms used by viruses to thwart host’s immune defenses
- A series of studies by researchers at University of Texas ( UT ) Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart host’s immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the... (Leggi Articolo)
- Viral-based therapies for cancer
- Researchers at Columbia University Medical Center continue to make progress in developing effective viral-based therapies for cancer. Two papers about promising research with genetically engineered viruses studied in mice, published in the journals Cancer Research and the Proceedings of the Na... (Leggi Articolo)
- Interferon beta-1a plus Natlizumab reduces multiple sclerosis relapse rate
- One-year data from the Phase III SENTINEL trial, presented at the 57th Annual Meeting - American Academy of Neurology ( AAN ), demonstrated that when Natalizumab ( Tysabri ) was added to Interferon beta-1a ( Avonex ) in patients with relapsing forms of multiple sclerosis ( MS ), the annualized cl... (Leggi Articolo)
- Morphine withdrawal complicates hepatitis C
- Researchers at the University of Pennsylvania have demonstrated that Morphine withdrawal complicates hepatitis C by suppressing IFN-alpha-mediated immunity and enhancing virus replication. The paper by Wang et al., Morphine withdrawal enhances hepatitis C virus ( HCV ) replicon expression, app... (Leggi Articolo)
- Erectile dysfunction: irreversible vision loss due phosphodiesterase 5 inhibitors
- Public Citizen, representing more than 135,000 U.S. consumers, submitted a petition to the FDA ( Food and Drug Administration ) to immediately add a black box warning regarding the risks of drug-induced blindness for the three phosphodiesterase 5 ( PDE5 ) inhibitors that are prescribed for the tr... (Leggi Articolo)
- Biochemical connection between hepatitis C virus and liver tumor
- Researchers at the University of Texas Medical Branch at Galveston ( UTMB ) have identified a key biochemical connection between the hepatitis C virus and liver cancer. According to Stanley M. Lemon, the senior author of a paper, the molecular mechanism is similar to the one that links the hum... (Leggi Articolo)
- Interferon beta-1a associated with cases of severe liver damage
- Avonex ( Interferon beta-1a ) is approved for the treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. FDA ( Food and Drug Administration ) and Biogen informed healthcare professio... (Leggi Articolo)
- B-cell non-Hodgkin's lymphoma and HCV infection: role of hepatitis C treatment
- Hepatitis C virus ( HCV ) plays a role in the development of both hepatocellular carcinoma and B-cell non-Hodgkin's lymphoma ( B-NHL ). A multicenter study, coordinated by D Vallisa, Department of Oncology and Hematology, G. da Saliceto Hospital, Piacenza ( Italy ), evaluated the role of anti... (Leggi Articolo)
- A novel type of T helper cells found to be a key to inflammatory diseases
- The molecular roots of inflammatory and autoimmune diseases such as asthma, arthritis, and multiple sclerosis ( MS ) have been discovered by a team of researchers led by The University of Texas M. D. Anderson Cancer Center. In an article in the Nature Immunology, the researchers report finding... (Leggi Articolo)
